Company: CRNX
Filing Date: 2025-01-10
Form Type: 8-K
Source: 0000950170-25-003801
Chunk: 0

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-01-10
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On January 10, 2025, Crinetics Pharmaceuticals, Inc. (the “ Company,” “ Crinetics,” “we,” “us,” or “our”) issued a press release and made available a corporate presentation announcing positive topline results from its open-label, Phase 2 congenital adrenal hyperplasia (“ CAH”) study of atumelnant, a novel, once-daily oral adrenocorticotropic hormone (“ ACTH”) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. Copies of the press release and corporate presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The press release and corporate presentation will also be available under the “ Investors” section of the Company’s website. The Company intends to deliver the corporate presentation during a conference call and live webcast with the investment community on January 10, 2025, at 8:30 a. m. Eastern Time.

The information contained in this Item 7.01 of this Current Report on Form 8-K, including in Exhibits 99.1 and 99.2 hereto, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.